Vonoprazan/amoxicillin/clarithromycin
Medication
From Wikipedia, the free encyclopedia
Vonoprazan/amoxicillin/clarithromycin, sold under the brand name Vonosap among others, is a co-packaged medication used for the treatment of Helicobacter pylori (H. pylori) infection.[1][4] It contains vonoprazan (as the fumarate), a potassium-competitive acid blocker; amoxicillin, a beta-lactam antibiotic; and clarithromycin, a macrolide antibiotic.[1][4]
Trade namesVonosap, Voquezna Triple Pak
| |
| Combination of | |
|---|---|
| Vonoprazan | Potassium-competitive acid blocker |
| Amoxicillin | Beta-lactam antibiotic |
| Clarithromycin | Macrolide antibiotic |
| Clinical data | |
| Trade names | Vonosap, Voquezna Triple Pak |
| License data | |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| KEGG | |
It was approved for medical use in Japan in 2016,[3] and in the United States in May 2022.[1][2][5][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[7][8]
